R A DeFronzo
Overview
Explore the profile of R A DeFronzo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
323
Citations
18030
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Abdelgani S, Puckett C, Adams J, Triplitt C, DeFronzo R, Abdul-Ghani M
J Clin Endocrinol Metab
. 2021 Aug;
106(12):3497-3504.
PMID: 34343296
Context: The results of the present study demonstrate that beta cell function in newly diagnosed T2DM patients is the key predictor of response to glucose lowering medications and provides a...
2.
Hassoun S, Al-Atrash M, Alkasim M, Dabbous Z, Mujahed O, DeFronzo R, et al.
Diabetes Metab
. 2016 Dec;
43(3):292-294.
PMID: 27932227
No abstract available.
3.
DeFronzo R, Chilton R, Norton L, Clarke G, Ryder R, Abdul-Ghani M
Diabetes Obes Metab
. 2016 Feb;
18(5):454-62.
PMID: 26919068
The recently completed EMPA-REG study showed that empagliflozin significantly decreased the major adverse cardiac events (MACE) endpoint, which comprised cardiovascular death, non-fatal myocardial infarction (MI) and stroke, in patients with...
4.
Coletta D, Fernandez M, Cersosimo E, Gastaldelli A, Musi N, DeFronzo R
Diabet Med
. 2014 Dec;
32(5):657-64.
PMID: 25484175
Aims: The molecular mechanisms by which muraglitazar (peroxisome proliferator-activated receptor γ/α agonist) improves insulin sensitivity in Type 2 diabetes mellitus are not fully understood. We hypothesized that muraglitazar would increase...
5.
Abdul-Ghani M, Puckett C, Triplitt C, Maggs D, Adams J, Cersosimo E, et al.
Diabetes Obes Metab
. 2014 Nov;
17(3):268-75.
PMID: 25425451
Aim: To test our hypothesis that initiating therapy with a combination of agents known to improve insulin secretion and insulin sensitivity in subjects with new-onset diabetes would produce greater, more...
6.
Farook V, Reddivari L, Chittoor G, Puppala S, Arya R, Fowler S, et al.
Pediatr Obes
. 2014 Nov;
10(4):320-7.
PMID: 25405847
Background/objectives: Although newer approaches have identified several metabolites associated with obesity, there is paucity of such information in paediatric populations, especially among Mexican-Americans (MAs) who are at high risk of...
7.
Abdul-Ghani M, DeFronzo R
J Intern Med
. 2014 Apr;
276(4):352-63.
PMID: 24690096
Maintaining normoglycaemia not only reduces the risk of diabetic microvascular complications but also corrects the metabolic abnormalities that contribute to the development and progression of hyperglycaemia, that is insulin resistance...
8.
Chittoor G, Farook V, Puppala S, Fowler S, Schneider J, Dyer T, et al.
Mol Hum Reprod
. 2013 May;
19(10):687-96.
PMID: 23689979
Preterm birth (PTB) is a complex trait, but little is known regarding its major genetic determinants. The objective of this study is to localize genes that influence susceptibility to PTB...
9.
Bray G, Smith S, Banerji M, Tripathy D, Clement S, Buchanan T, et al.
Diabetes Obes Metab
. 2013 Apr;
15(10):931-7.
PMID: 23551856
Aims: This study examined the effects of pioglitazone on body weight and bone mineral density (BMD) prospectively in patients with impaired glucose tolerance as pioglitazone (TZD) increases body weight and...
10.
Guardado-Mendoza R, Jimenez-Ceja L, Majluf-Cruz A, Kamath S, Fiorentino T, Casiraghi F, et al.
Int J Obes (Lond)
. 2012 Dec;
37(8):1071-8.
PMID: 23229736
Objective: Obesity is associated with high insulin and glucagon plasma levels. Enhanced β-cell function and β-cell expansion are responsible for insulin hypersecretion. It is unknown whether hyperglucagonemia is due to...